Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GRTX | Common Stock | Sale | -$90.2K | -400K | -7.58% | $0.23 | 4.88M | Jan 11, 2024 | See fn. | F1 |
transaction | GRTX | Common Stock | Sale | -$4.6K | -20K | -0.41% | $0.23 | 4.86M | Mar 22, 2024 | See fn. | F1 |
transaction | GRTX | Common Stock | Sale | -$171K | -780K | -16.05% | $0.22 | 4.08M | Mar 25, 2024 | See fn. | F1 |
transaction | GRTX | Common Stock | Sale | -$393K | -2M | -49.02% | $0.20 | 2.08M | Mar 26, 2024 | See fn. | F1 |
transaction | GRTX | Common Stock | Sale | -$52.1K | -307K | -14.76% | $0.17 | 1.77M | Mar 27, 2024 | See fn. | F1 |
transaction | GRTX | Common Stock | Sale | -$101K | -693K | -39.09% | $0.15 | 1.08M | Mar 28, 2024 | See fn. | F1 |
Altamont Pharmaceutical Holdings, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Id | Content |
---|---|
F1 | Mark Pearson is the Manager and sole Member of Altamont Pharmaceutical Holdings LLC ("Altamont"). Altamont owns 5,280,000 shares of Galera Therapeutics, Inc. Mark Pearson does not personally own any shares. As the Manager and sole Member of Altamont, Mark Pearson possesses the power to vote and dispose of or direct the disposition of 5,280,000 shares. |